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Using data from the Geneva Cancer Registry, we found that in 2002–2004, breast cancer incidence in women aged 25–39 years
increased by 46.7% per year (95% CI: 7.1–74.0, P¼0.015), which surveillance or detection bias may not fully explain.
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Health professionals and patient support groups in Geneva,
Switzerland, have recently expressed concern about an apparently
increasing number of very young breast cancer patients. Owing to
the average 2-year delay in cancer registration, we have only now
been able to investigate this observation using incidence data up to
the year 2004 among women residents in Geneva.
MATERIALS AND METHODS
The Geneva cancer registry, functional since 1970 and covering the
whole population of the canton (approximately 435000 inhabi-
tants), is considered comprehensive with a low percentage (o2%)
of cases recorded from death certificates only (Bouchardy, 1997).
Trained staff systematically abstract data from reports of all
pathology laboratories and public hospitals. Private practitioners
regularly fill out questionnaires to complete missing clinical and
therapeutic data; death certificates are systematically consulted.
We included all incident invasive breast cancer cases diagnosed
in the resident population of the canton between 1995 and 2004
(n¼3608), with the population at risk considered as the resident
population at the middle of each relevant year, obtained from the
Cantonal Population Office. We calculated annual incidence rates
for five age groups: 25–39, 40–49, 50–69, 70–79, and X80 years.
Trends in age-specific annual incidence rates were calculated by
log-linear Poisson regression implemented in the generalised
linear interactive modelling statistical package (Francis et al,
1993). We calculated mean annual rates of increase over the whole
period to test for a continuous progressive increase and calculated
the mean annual rates for the last 3-year period only to test for a
recent, sudden increase. For women aged 25–39 years, we
compared patient and tumour characteristics before and when
the increase occurred by w
2 test for heterogeneity.
Variables of interest included family history of breast or ovarian
cancer (positive if one first-degree or two second-degree relatives
were affected, and negative), method of detection (mammography
or clinical screening, breast self-examination, symptoms or other),
modalities of diagnostic assessment (clinical status, mammo-
graphy or ultrasound, magnetic resonance imaging (MRI): yes vs
no), histological type (ductal: ICD-O code 8500, lobular: ICD-0
code 8520 and 8522, and other), differentiation (grades I–III, and
unknown coded according to the International Classification of
Diseases for Oncology, ICD-O (ICD-O International Classification
of Diseases for Oncology, 1976)), oestrogen and progesterone
receptor status (positive (if X10% of cells expressed receptors),
negative, and unknown), mean pathological tumour size (in mm),
and stage (coded according to the tumour, node and metastasis
TNM classification (TNM Classification of malignant tumours,
1992)). We used the pathologic pTNM classification system or,
when absent, the clinical cTNM classification. Tumour stage was
considered as stage I (T1 and N0), stage II (T0 or T1 and N1, T2
and N0 or N1, T3 and N0), stage III (T0 or T1 or T2 and N2, T3 and
N1 or N2, T4 and any N, any T and N3), stage IV (M1) and
unknown. We also examined the proportion of tumours with
clinical T0 N0 M0.
RESULTS
For women aged 25–39 years, breast cancer rates were steady until
2002 and increased sharply thereafter, being 19.7 per 100000 in
1995, rising to 53.9 per 100000 in 2004 (Figure 1). Table 1 presents
results of trend tests for the period 1995–2004 (middle columns)
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annual increase was 8.7% (95% CI: 2.8–15.0, P¼0.003) over the
whole period. The entire increase occurred in the last 3-year period
(2002–2004) with a mean annual increase of 46.7% (95% CI: 7.1–
74.0%, P¼0.015). Cancers at ages 25–39 represented 3.4% of all
breast cancers in 1995 and 7.2% in 2004 (P¼0.032). Also, since
1970 (when cancer registration started in Geneva) no such increase
has been observed (data not shown). For the other age groups,
incidence remained fairly stable, except for women aged 50–69
years among whom it increased at an average of 2.6% per year,
from 1998 to 2002, when it stabilised (Table 1, Figure 1).
Table 2 shows tumour characteristics among women aged 25–39
years in 1995–2001 and 2002–2004. We found a significant
increase in diagnoses diagnosed by MRI. In particular, 26% of
breast cancers in young women were diagnosed by MRI in 1995–
2001 compared with 48% in 2002–2004 (P¼0.006). Screen-
detected cancers increased non-significantly from 9 to 19%. The
proportion of stage I cancers slightly decreased from 40 to 33%,
whereas the proportion of stage II cancers remained relatively
constant around 45%. Only three women had non-clinical T0 N0
tumours, one in the first and two in the second period. The mean
tumour size remained unchanged over the whole study period, at
21mm in 1995–2001 and 20mm in 2002–2004 (P¼0.817). We
observed no increase in the proportion of young patients with a
positive familial history of breast cancer.
DISCUSSION
In Geneva, breast cancer incidence in women aged o40 years has
recently doubled. This increase may be partly explained by a
higher screening frequency of younger women and better
Women aged 25–39 years 
Year 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Patients N 10 13 15 11 15 12 16 13 21 29 
Women at risk N  50 762 51 117 51 125 51 116 51 342 51 769 52 350 52 967 53 606 53 831 
Incidence rates 19.7 25.4 29.3 21.5 29.2 23.2 30.6 24.5 39.2 53.9 
per 100 000 
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Figure 1 Trends(logarithmic scale) in annual breast cancer incidence rates by age group in Geneva, Switzerland.
Table 1 Mean annual increase of breast cancer incidence rates by age group for the whole study period and for the last 3-year period and P-value for
trend tests
Incidence rates per 100000 Trend test for the whole study period 1995–2004
a
Trend test for the last 3-year period
of the study 2002–2004
b
Age 1995 2004 Mean annual increase (95% CI) P-value Mean annual increase (95% CI) P-value
25–39 19.7 53.9 +8.7 (2.8–15.0) 0.003 +46.7 (7.1–100.8) 0.015
40–49 187.3 198.8  0.6 ( 2.8–3.4) 0.700 +5.4 ( 11.6–27.7) 0.555
50–69 312.4 400.2 +2.6 (1.0–4.2) 0.001  1.7 ( 11.7–8.3) 0.737
70–79 332.6 383.5  0.4 ( 2.3–3.3) 0.756 +11.0 ( 7.1–32.6) 0.247
X80 330.7 381.4 +0.9 ( 2.5–4.5) 0.590 +3.1 ( 16.9–27.8) 0.781
CI¼confidence interval.
aPoisson regression testing trends of annual incidence rates during the period 1995–2004.
bPoisson regression testing trends of annual incidence rates
during the period 2002–2004.
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tumour detection through advances in imaging techniques may
also be involved, since in 1995–2001 less than 30% of breast cancer
diagnoses in young women involved MRI compared with nearly
50% in 2002–2004 (P¼0.006).
Nevertheless, these detection biases seem unlikely to explain
fully the observed incidence increase. Screening and improvement
in diagnostic techniques should lead to a shift in stage distribution
towards earlier stages, whereas in our population, this did not
change significantly, and the proportion of clinically palpable
tumours remained constant. The screening programme imple-
mented in Geneva 10 years ago targets women aged 50–69 years,
and screening for breast cancer in women o40 years is rare (Lutz
et al, 2000). Furthermore, the proportion of patients reporting a
positive family history has remained relatively stable around 30%
between the two periods. We can also reasonably rule out an
increase in fortuitous discovery of contralateral breast cancer as
only two women were diagnosed with synchronous breast cancer
in 2002 and 2003 respectively.
Although significant, our observation is based on only 63
patients diagnosed in 2002–2004, and should be interpreted with
caution. With respect to any change in population estimates, the
young resident female population grew smoothly over the study
period, with no sudden increase in 2002–2004 (Figure 1). Among
other cancer sites of women aged 25–39 years, we found a
significant increase of melanoma (mean annual increase of 6.9%;
95% CI: 0.3–13.8, P¼0.038) starting early in the study period, but
this is already a well-documented phenomenon in Switzerland
(Association of Swiss Cancer Registries (ASCR), 2002).
Other reasons should be explored to explain this increase in
breast cancer incidence in younger women. Most known breast
cancer risk factors, including nulliparity or later age at first full-
term pregnancy, early menarche, dietary habits, alcohol intake,
and lack of physical activity, apply at all ages. However, some other
factors, such as family history of breast and/or ovarian cancer, in
utero exposure, oral contraceptive use, smoking, and breast
radiation are more relevant to young women (Yankaskas, 2005;
Colditz et al, 2006).
In Geneva, prevalence of obesity has increased among
adolescents and young females (Morabia and Costanza, 2005),
but, in contrast to post-menopausal women, it appears to be
protective against breast cancer in young women (Bouchardy et al,
1990; Magnusson et al, 2005; Michels et al, 2006). Smoking still
seems to be increasing among women in Geneva and, compared
with older women, young women begin smoking cigarettes at a
much earlier age and are heavier smokers (Costanza et al, 2006).
Table 2 Comparison of tumour assessment and characteristics of breast cancer patients aged o40 years before and after the increase began
1995–2001 2002–2004
Patient and tumour characteristics Number (%) Number (%) P-value for heterogeneity test
Age at diagnosis
25–29 years 6 (7) 6 (10) 0.523
30–34 years 32 (35) 17 (27)
35–39 years 54 (59) 40 (64)
Method of detection
Screening 8 (9) 12 (19) 0.168
Breast self-examination 66 (72) 40 (64)
Symptoms, other 18 (20) 11 (18)
Diagnostic assessment
Clinical status
a 81 (88) 58 (92) 0.419
Mammography or ultrasound
a 80 (87) 56 (88) 0.719
MRI
a 24 (26) 30 (48) 0.006
Family history
Negative 64 (70) 41 (65) 0.557
Positive 28 (30) 22 (35)
Stage
I 37 (40) 21 (33) 0.673
II 41 (45) 27 (43)
III 7 (8) 9 (14)
IV 4 (4) 3 (5)
Unknown 3 (3) 3 (5)
Histology
Ductal 81 (88) 60 (95) 0.078
Lobular 0 (0) 1 (2)
Other 11 (12) 2 (3)
Grade
I 15 (16) 8 (13) 0.217
II 33 (36) 33 (52)
III 38 (41) 20 (32)
Unknown 6 (7) 2 (3)
Oestrogen receptor status
Negative 33 (36) 18 (29) 0.630
Positive 56 (61) 43 (68)
Unknown 3 (3) 2 (3)
Progesterone receptor status
Negative 37 (40) 25 (40) 0.997
Positive 52 (57) 36 (57)
Unknown 3 (3) 2 (3)
Total 92 (100) 63 (100)
MRI¼magnetic resonance imaging.
aBinary variables classified as yes vs no.
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accepted although any impact could be greater on young women
(Miller et al, 2007). In this study, we can exclude an association
with previous cancer treatment, given that only one woman was so
affected (bilateral ovarian cancer).
In comparison, for Europe and the United States, we found no
recent or sudden increase in breast cancer incidence among
women under 40 years in the two main public-use cancer registry
data sets, the Surveillance Epidemiology and End Results (SEER)
and Cancer Incidence in Five Continents (CIF) (International
Agency for Research on Cancer (IARC), 2002; National Cancer
Institute (NCI), 2004). However, the latest available years were
1997 for CIF and 2003 for SEER.
In conclusion, we observed a significant increase in young
breast cancer patients. At present, we cannot definitively rule out
an increased surveillance and detection bias and we cannot
confidently conclude a sustained increase. Careful surveillance of
recent trends of breast cancer incidence is required for young
women. If other population-based cancer registries confirm this
trend, further research on breast cancer risk factors, including any
acting in utero and early in life, would be indicated.
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